Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-01-09

AUTHORS

Gabriele Arendt, Svenja Schlonies, Eser Orhan, Olaf Stüve

ABSTRACT

Modern antiretroviral combination therapy (cART) has transformed HIV from a life-threatening infection into a chronic disease. However, the life-long treatment has side effects that frequently have a negative impact on patients’ quality of life. Thus, there are some efforts to “simplify” therapy, i.e. apply regimens with three or fewer antiretroviral substances. However, neurologists are relatively sceptical towards this cART “simplification”, because the capacity of simplified regimens to access the cerebrospinal fluid (CSF) might be too weak to effectively suppress viral load in this compartment. Thus, data of a big Neuro-AIDS cohort of 4992 HIV-positive patients consecutively recruited over three decades were retrospectively analysed in terms of neurocognitive performance of patients switched to simplified therapy regimens. To test whether simplified drug regimens result in new neuropsychological deficits or the worsening of pre-existing ones in HIV+ patients. Three groups of HIV+ patients were switched from triple therapy to three different two drug regimens (n = 177 to lamivudine/PI, n = 37 to INI/PI, and n = 303 to dual PI); three other groups of patients put from one to an alternative triple combination (n = 290 ABC/3TC/PI, n = 244 TDF/FTC/PI, and n = 158 TDF/FTC/NNRTI) for whatever reason served as controls. All patients were followed up over 4 years maximum. Every patient group improved immunologically and virologically after the switch. However, patients who switched to INI/PI combinations remained stable in neuropsychological tests, while a considerable percentage of patients who switched to other treatments demonstrated a decline. Remarkably, a high percentage of the patients switched to “simplified drug regimens” was not well-controlled virologically before the switch. HIV-positive patients with simplified therapy regimens show some benefit in terms of systemic infection surrogate markers (CD4 ± cell count and plasma viral load); however, neurocognitive deficits do not improve, but remain stable in most cases. More... »

PAGES

174-182

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13365-018-0701-x

DOI

http://dx.doi.org/10.1007/s13365-018-0701-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111308166

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30628025


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiretroviral Therapy, Highly Active", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cognition", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cognitive Dysfunction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Emtricitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Protease Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lamivudine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuropsychological Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reverse Transcriptase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tenofovir", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arendt", 
        "givenName": "Gabriele", 
        "id": "sg:person.0675033774.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675033774.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schlonies", 
        "givenName": "Svenja", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Orhan", 
        "givenName": "Eser", 
        "id": "sg:person.016013432171.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016013432171.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Southwestern Medical Center, University of Texas, Dallas, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.416214.4", 
          "name": [
            "Southwestern Medical Center, University of Texas, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "St\u00fcve", 
        "givenName": "Olaf", 
        "id": "sg:person.01133360405.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133360405.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12879-017-2311-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084250354", 
          "https://doi.org/10.1186/s12879-017-2311-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00315660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018109859", 
          "https://doi.org/10.1007/bf00315660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13365-018-0626-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101534995", 
          "https://doi.org/10.1007/s13365-018-0626-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-017-2755-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092000963", 
          "https://doi.org/10.1186/s12879-017-2755-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01-09", 
    "datePublishedReg": "2019-01-09", 
    "description": "Modern antiretroviral combination therapy (cART) has transformed HIV from a life-threatening infection into a chronic disease. However, the life-long treatment has side effects that frequently have a negative impact on patients\u2019 quality of life. Thus, there are some efforts to \u201csimplify\u201d therapy, i.e. apply regimens with three or fewer antiretroviral substances. However, neurologists are relatively sceptical towards this cART \u201csimplification\u201d, because the capacity of simplified regimens to access the cerebrospinal fluid (CSF) might be too weak to effectively suppress viral load in this compartment. Thus, data of a big Neuro-AIDS cohort of 4992 HIV-positive patients consecutively recruited over three decades were retrospectively analysed in terms of neurocognitive performance of patients switched to simplified therapy regimens. To test whether simplified drug regimens result in new neuropsychological deficits or the worsening of pre-existing ones in HIV+ patients. Three groups of HIV+ patients were switched from triple therapy to three different two drug regimens (n\u2009=\u2009177 to lamivudine/PI, n\u2009=\u200937 to INI/PI, and n\u2009=\u2009303 to dual PI); three other groups of patients put from one to an alternative triple combination (n\u2009=\u2009290 ABC/3TC/PI, n\u2009=\u2009244 TDF/FTC/PI, and n\u2009=\u2009158 TDF/FTC/NNRTI) for whatever reason served as controls. All patients were followed up over 4\u00a0years maximum. Every patient group improved immunologically and virologically after the switch. However, patients who switched to INI/PI combinations remained stable in neuropsychological tests, while a considerable percentage of patients who switched to other treatments demonstrated a decline. Remarkably, a high percentage of the patients switched to \u201csimplified drug regimens\u201d was not well-controlled virologically before the switch. HIV-positive patients with simplified therapy regimens show some benefit in terms of systemic infection surrogate markers (CD4 \u00b1 cell count and plasma viral load); however, neurocognitive deficits do not improve, but remain stable in most cases.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13365-018-0701-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1114176", 
        "issn": [
          "1355-0284", 
          "1538-2443"
        ], 
        "name": "Journal of NeuroVirology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "combination antiretroviral therapy", 
      "HIV-positive patients", 
      "drug regimens", 
      "therapy regimens", 
      "cerebrospinal fluid", 
      "life-long treatment", 
      "antiretroviral combination therapy", 
      "group of patients", 
      "life-threatening infections", 
      "quality of life", 
      "triple therapy", 
      "antiretroviral therapy", 
      "viral load", 
      "combination therapy", 
      "patient group", 
      "surrogate marker", 
      "chronic diseases", 
      "regimens", 
      "side effects", 
      "patients", 
      "triple combination", 
      "neuropsychological deficits", 
      "neurocognitive deficits", 
      "therapy", 
      "PI combinations", 
      "neurocognitive performance", 
      "neuropsychological tests", 
      "considerable percentage", 
      "high percentage", 
      "treatment", 
      "real-life experience", 
      "deficits", 
      "group", 
      "most cases", 
      "HIV", 
      "neurologists", 
      "cohort", 
      "worsening", 
      "infection", 
      "pre-existing ones", 
      "disease", 
      "percentage", 
      "brain", 
      "markers", 
      "years", 
      "negative impact", 
      "combination", 
      "compartments", 
      "decline", 
      "control", 
      "cases", 
      "life", 
      "substances", 
      "benefits", 
      "test", 
      "effect", 
      "fluid", 
      "experience", 
      "data", 
      "quality", 
      "reasons", 
      "impact", 
      "decades", 
      "capacity", 
      "efforts", 
      "terms", 
      "switch", 
      "load", 
      "one", 
      "performance", 
      "simplification", 
      "Modern antiretroviral combination therapy", 
      "antiretroviral substances", 
      "big Neuro-AIDS cohort", 
      "Neuro-AIDS cohort", 
      "new neuropsychological deficits", 
      "alternative triple combination", 
      "INI/PI combinations", 
      "simplified drug regimens", 
      "simplified therapy regimens", 
      "systemic infection surrogate markers", 
      "infection surrogate markers"
    ], 
    "name": "Simplification of combination antiretroviral therapy (cART) and the brain\u2014a real-life experience", 
    "pagination": "174-182", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111308166"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13365-018-0701-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30628025"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13365-018-0701-x", 
      "https://app.dimensions.ai/details/publication/pub.1111308166"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_803.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13365-018-0701-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13365-018-0701-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13365-018-0701-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13365-018-0701-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13365-018-0701-x'


 

This table displays all metadata directly associated to this object as RDF triples.

271 TRIPLES      22 PREDICATES      134 URIs      121 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13365-018-0701-x schema:about N0c82e9c87127429188f67ab8615cd301
2 N1ae2d01899de48d3844dfbb9a395d490
3 N2c0fc8a01a0548b1822b2c72a47281ad
4 N2d4bfd6333864a0599b3fc48be82731d
5 N356b996fb97545b29da6015bce8e18ce
6 N42b2d910296542f49118a4a67c5a12f0
7 N482c08ab53c74dfb87593bdae4c175c0
8 N4e3c4ad944414a2bb2e9b4ee40b4a4ee
9 N64354a6b89864dd99f70c1dcf1a2cb3d
10 N65b93e80b0934ac2bc84f035168f0b8e
11 N665941f9f65f42cead52befeb4ddf9dc
12 N67de60f205534579a6016cf9ea277260
13 N7a16abb62bbe4ec6bff9408fa38cc2c3
14 N8ed7f00d3e1b4eb98475017a8341ec33
15 N985197f324f4436891593d9436d1da01
16 Na8c4531c8a334977848f1c2db21b7337
17 Nb5b6a9d94897415dac5041b2987303b4
18 Nbe3c2ca8170740e9a311cc9835cc3aaa
19 Nc27ccbb7f3134878a35e971dca87c0fc
20 Nd03f8a56a85c43b2b826ffc614b9c75b
21 Nd1bba73bf0924394a3e47b132776235e
22 anzsrc-for:11
23 anzsrc-for:1103
24 anzsrc-for:1108
25 schema:author N7fdbc313dd3e4fbdb390a48e74a5ea9d
26 schema:citation sg:pub.10.1007/bf00315660
27 sg:pub.10.1007/s13365-018-0626-4
28 sg:pub.10.1186/s12879-017-2311-2
29 sg:pub.10.1186/s12879-017-2755-4
30 schema:datePublished 2019-01-09
31 schema:datePublishedReg 2019-01-09
32 schema:description Modern antiretroviral combination therapy (cART) has transformed HIV from a life-threatening infection into a chronic disease. However, the life-long treatment has side effects that frequently have a negative impact on patients’ quality of life. Thus, there are some efforts to “simplify” therapy, i.e. apply regimens with three or fewer antiretroviral substances. However, neurologists are relatively sceptical towards this cART “simplification”, because the capacity of simplified regimens to access the cerebrospinal fluid (CSF) might be too weak to effectively suppress viral load in this compartment. Thus, data of a big Neuro-AIDS cohort of 4992 HIV-positive patients consecutively recruited over three decades were retrospectively analysed in terms of neurocognitive performance of patients switched to simplified therapy regimens. To test whether simplified drug regimens result in new neuropsychological deficits or the worsening of pre-existing ones in HIV+ patients. Three groups of HIV+ patients were switched from triple therapy to three different two drug regimens (n = 177 to lamivudine/PI, n = 37 to INI/PI, and n = 303 to dual PI); three other groups of patients put from one to an alternative triple combination (n = 290 ABC/3TC/PI, n = 244 TDF/FTC/PI, and n = 158 TDF/FTC/NNRTI) for whatever reason served as controls. All patients were followed up over 4 years maximum. Every patient group improved immunologically and virologically after the switch. However, patients who switched to INI/PI combinations remained stable in neuropsychological tests, while a considerable percentage of patients who switched to other treatments demonstrated a decline. Remarkably, a high percentage of the patients switched to “simplified drug regimens” was not well-controlled virologically before the switch. HIV-positive patients with simplified therapy regimens show some benefit in terms of systemic infection surrogate markers (CD4 ± cell count and plasma viral load); however, neurocognitive deficits do not improve, but remain stable in most cases.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N0c2e11ecf39749938bd4d8de302efaf9
37 N2691895f93b844018735b3f76c2d69c8
38 sg:journal.1114176
39 schema:keywords HIV
40 HIV-positive patients
41 INI/PI combinations
42 Modern antiretroviral combination therapy
43 Neuro-AIDS cohort
44 PI combinations
45 alternative triple combination
46 antiretroviral combination therapy
47 antiretroviral substances
48 antiretroviral therapy
49 benefits
50 big Neuro-AIDS cohort
51 brain
52 capacity
53 cases
54 cerebrospinal fluid
55 chronic diseases
56 cohort
57 combination
58 combination antiretroviral therapy
59 combination therapy
60 compartments
61 considerable percentage
62 control
63 data
64 decades
65 decline
66 deficits
67 disease
68 drug regimens
69 effect
70 efforts
71 experience
72 fluid
73 group
74 group of patients
75 high percentage
76 impact
77 infection
78 infection surrogate markers
79 life
80 life-long treatment
81 life-threatening infections
82 load
83 markers
84 most cases
85 negative impact
86 neurocognitive deficits
87 neurocognitive performance
88 neurologists
89 neuropsychological deficits
90 neuropsychological tests
91 new neuropsychological deficits
92 one
93 patient group
94 patients
95 percentage
96 performance
97 pre-existing ones
98 quality
99 quality of life
100 real-life experience
101 reasons
102 regimens
103 side effects
104 simplification
105 simplified drug regimens
106 simplified therapy regimens
107 substances
108 surrogate marker
109 switch
110 systemic infection surrogate markers
111 terms
112 test
113 therapy
114 therapy regimens
115 treatment
116 triple combination
117 triple therapy
118 viral load
119 worsening
120 years
121 schema:name Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience
122 schema:pagination 174-182
123 schema:productId N1605fc4e40834fb09571e8ed4e17bc48
124 N84169c3c56854ab585ab14ef4fd2b2d3
125 N9cddbc0281ef44c59879e852f4112548
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111308166
127 https://doi.org/10.1007/s13365-018-0701-x
128 schema:sdDatePublished 2021-12-01T19:43
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher N4015bbf355cf41f983a6fb46faa73f1b
131 schema:url https://doi.org/10.1007/s13365-018-0701-x
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N0c2e11ecf39749938bd4d8de302efaf9 schema:volumeNumber 25
136 rdf:type schema:PublicationVolume
137 N0c82e9c87127429188f67ab8615cd301 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Reverse Transcriptase Inhibitors
139 rdf:type schema:DefinedTerm
140 N1605fc4e40834fb09571e8ed4e17bc48 schema:name pubmed_id
141 schema:value 30628025
142 rdf:type schema:PropertyValue
143 N1ae2d01899de48d3844dfbb9a395d490 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N2691895f93b844018735b3f76c2d69c8 schema:issueNumber 2
147 rdf:type schema:PublicationIssue
148 N2c0fc8a01a0548b1822b2c72a47281ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Tenofovir
150 rdf:type schema:DefinedTerm
151 N2d4bfd6333864a0599b3fc48be82731d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Retrospective Studies
153 rdf:type schema:DefinedTerm
154 N356b996fb97545b29da6015bce8e18ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Antiretroviral Therapy, Highly Active
156 rdf:type schema:DefinedTerm
157 N4015bbf355cf41f983a6fb46faa73f1b schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 N42b2d910296542f49118a4a67c5a12f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adult
161 rdf:type schema:DefinedTerm
162 N482c08ab53c74dfb87593bdae4c175c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Cognitive Dysfunction
164 rdf:type schema:DefinedTerm
165 N4e3c4ad944414a2bb2e9b4ee40b4a4ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Neuropsychological Tests
167 rdf:type schema:DefinedTerm
168 N64354a6b89864dd99f70c1dcf1a2cb3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Severity of Illness Index
170 rdf:type schema:DefinedTerm
171 N65b93e80b0934ac2bc84f035168f0b8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Cognition
173 rdf:type schema:DefinedTerm
174 N665941f9f65f42cead52befeb4ddf9dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Quality of Life
176 rdf:type schema:DefinedTerm
177 N67de60f205534579a6016cf9ea277260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Lamivudine
179 rdf:type schema:DefinedTerm
180 N6d596b45f41c4ff282122a1018c0781f rdf:first N7e2cbd36cae24d62992198fc8b0afb1a
181 rdf:rest Nb8b8fec790e441ed9f82090edfe2df29
182 N7a16abb62bbe4ec6bff9408fa38cc2c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name HIV Protease Inhibitors
184 rdf:type schema:DefinedTerm
185 N7e2cbd36cae24d62992198fc8b0afb1a schema:affiliation grid-institutes:None
186 schema:familyName Schlonies
187 schema:givenName Svenja
188 rdf:type schema:Person
189 N7fdbc313dd3e4fbdb390a48e74a5ea9d rdf:first sg:person.0675033774.25
190 rdf:rest N6d596b45f41c4ff282122a1018c0781f
191 N84169c3c56854ab585ab14ef4fd2b2d3 schema:name doi
192 schema:value 10.1007/s13365-018-0701-x
193 rdf:type schema:PropertyValue
194 N8ed7f00d3e1b4eb98475017a8341ec33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Middle Aged
196 rdf:type schema:DefinedTerm
197 N985197f324f4436891593d9436d1da01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Male
199 rdf:type schema:DefinedTerm
200 N9cddbc0281ef44c59879e852f4112548 schema:name dimensions_id
201 schema:value pub.1111308166
202 rdf:type schema:PropertyValue
203 Na8c4531c8a334977848f1c2db21b7337 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Aging
205 rdf:type schema:DefinedTerm
206 Nb5b6a9d94897415dac5041b2987303b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Emtricitabine
208 rdf:type schema:DefinedTerm
209 Nb8b8fec790e441ed9f82090edfe2df29 rdf:first sg:person.016013432171.40
210 rdf:rest Nccc1d39f6a974846a1dc5c410601eedf
211 Nbe3c2ca8170740e9a311cc9835cc3aaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Female
213 rdf:type schema:DefinedTerm
214 Nc27ccbb7f3134878a35e971dca87c0fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name HIV Infections
216 rdf:type schema:DefinedTerm
217 Nccc1d39f6a974846a1dc5c410601eedf rdf:first sg:person.01133360405.77
218 rdf:rest rdf:nil
219 Nd03f8a56a85c43b2b826ffc614b9c75b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name HIV-1
221 rdf:type schema:DefinedTerm
222 Nd1bba73bf0924394a3e47b132776235e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Brain
224 rdf:type schema:DefinedTerm
225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
226 schema:name Medical and Health Sciences
227 rdf:type schema:DefinedTerm
228 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
229 schema:name Clinical Sciences
230 rdf:type schema:DefinedTerm
231 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
232 schema:name Medical Microbiology
233 rdf:type schema:DefinedTerm
234 sg:journal.1114176 schema:issn 1355-0284
235 1538-2443
236 schema:name Journal of NeuroVirology
237 schema:publisher Springer Nature
238 rdf:type schema:Periodical
239 sg:person.01133360405.77 schema:affiliation grid-institutes:grid.416214.4
240 schema:familyName Stüve
241 schema:givenName Olaf
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133360405.77
243 rdf:type schema:Person
244 sg:person.016013432171.40 schema:affiliation grid-institutes:None
245 schema:familyName Orhan
246 schema:givenName Eser
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016013432171.40
248 rdf:type schema:Person
249 sg:person.0675033774.25 schema:affiliation grid-institutes:None
250 schema:familyName Arendt
251 schema:givenName Gabriele
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675033774.25
253 rdf:type schema:Person
254 sg:pub.10.1007/bf00315660 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018109859
255 https://doi.org/10.1007/bf00315660
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s13365-018-0626-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101534995
258 https://doi.org/10.1007/s13365-018-0626-4
259 rdf:type schema:CreativeWork
260 sg:pub.10.1186/s12879-017-2311-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084250354
261 https://doi.org/10.1186/s12879-017-2311-2
262 rdf:type schema:CreativeWork
263 sg:pub.10.1186/s12879-017-2755-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092000963
264 https://doi.org/10.1186/s12879-017-2755-4
265 rdf:type schema:CreativeWork
266 grid-institutes:None schema:alternateName Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, Düsseldorf, Germany
267 schema:name Department of Neurology, Medical Faculty, University of Duesseldorf, Moorenstr, 5, 40225, Düsseldorf, Germany
268 rdf:type schema:Organization
269 grid-institutes:grid.416214.4 schema:alternateName Southwestern Medical Center, University of Texas, Dallas, TX, USA
270 schema:name Southwestern Medical Center, University of Texas, Dallas, TX, USA
271 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...